PureTech subsidiary licences microbiome-based therapy
PureTech Health subsidiary Commense Inc has licensed a microbiome-based therapy to prevent asthma and other allergic diseases from the University of British Columbia.
PURETECH HEALTH
£1.72
17:35 15/11/24
-1.15%
-£0.02
"This live biotherapeutic product bolsters Commense's pipeline of novel therapeutic programs designed to nurture a healthy microbiome early in life," the company said.